Core Perspective - The company has completed its rebranding from Avant Technologies to Avaà Bio, reflecting a focused commitment to developing cell-based therapies for diabetes and age-related disorders [1] Company Overview - Avaà Bio, Inc. is an emerging biotechnology company that specializes in genetically modified cell lines and aims to develop innovative cell-based therapies through joint ventures and licensing agreements [1] Rebranding Details - The rebranding to Avaà Bio is effective as of February 11, 2026, and the company's stock will continue to trade under the ticker symbol AVAI on OTC Markets [1] - The new corporate identity aims to align with the company's core operations in sourcing, developing, and protecting advanced cellular therapies [1] Pipeline Highlights - **Diabetes Development Program**: Focuses on genetically modified cell lines designed to produce, store, and secrete insulin, combined with proprietary encapsulation for immune protection, targeting type 1 and insulin-dependent type 2 diabetes [1] - **Klotho Development Program**: Aims to advance a "longevity protein" overexpression cell line to address age-related decline and broader anti-aging applications [1] - The company has formed strategic collaborations, including Insulinova for the diabetes program and Klothonova for the Klotho program, to enhance clinical translation through joint research and licensing [1] Strategic Vision - The rebranding is seen as a pivotal moment in the company's evolution, positioning it to attract high-quality partnerships, accelerate research and development, and bring innovative treatments closer to patients [1]

Type 1 Diabetes (T1D) Program - Sana's hypoimmune platform (HIP) overcomes allogeneic rejection in people, which is confirmed by 4-week and 12-week data[4] - Type 1 diabetes affects 94 million children and adults, and is projected to affect 164 million by 2040[12, 13] - Type 1 diabetes leads to 201600 deaths per year and costs $81 billion worldwide annually[17] - SC451, a HIP-modified stem cell-derived pancreatic islet therapy, is advancing toward the clinic with an expected IND filing as early as 2026[114] - HIP-modified PSC differentiated islet cells transplanted into muscle persist & control blood glucose in mice for >15 months[64] Autoimmune Disease Program - B-cell mediated autoimmune diseases affect >5 million patients[68] - SC291, a HIP-modified CD19 CAR T, leads to deep B-cell depletion and has significant potential in B-cell mediated autoimmune diseases, with an ongoing GLEAM study[114] - Sana's T cell manufacturing process provides ~85% full knock-out of MHC class I and II, >995% TCR negative cells[79] - Fusogen platform offers the potential to treat B-cell mediated autoimmune diseases and B-cell cancers with NO lymphodepletion with an expected IND filing as early as 2026[114] Oncology Program - SC262, a HIP-modified CD22 CAR T, has meaningful potential in treating CD19 CAR T relapsed patients, with an ongoing VIVID study[114] - Estimated ~12000 B cell malignancy patients treated with CD19 CAR T in 2027, with ~35-40% durable complete responses, leading to ~7500 CAR T failures annually[106]